Skip to content
Home/Companies/Healthcare/Avalyn Pharma
AP

Avalyn Pharma

Healthcare·France·Exited 2026·Held 9yr

Avalyn Pharma is a healthcare company, headquartered in France.

Entry
2017
Hold
9yr
Exit
2026
Est. EV
–

Who owns Avalyn Pharma?

Avalyn Pharma was owned by Andera Partners through BioDiscovery 5 (2017 vintage) from 2017 to 2026, exited via IPO.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Andera Partners
Investor
Andera Partners
BioDiscovery 5 · 2017 · VC

Key facts

HQFrance
SectorHealthcare
Exit Type
IPO
Buyer
MOIC
–
Exit Year
2026

More from BioDiscovery 5

Other portfolio companies in the same fund.

Amolyt Pharma
Exited 2024
HealthcareFrance· 2021
to
Evommune
Exited 2025
HealthcareFrance· 2021
to
Nyxoah
Active
HealthcareBelgium· 2020
AgoMab
Exited 2026
HealthcareFrance· 2019
to
AM Pharma
Active
HealthcareNetherlands· 2019
Arvelle
Exited 2021
HealthcareSwitzerland· 2019
to

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
4ways
Active
ECI PartnersUK
A Place for Mom
Active
Silver LakeUS
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abbisko Healthcare
Active
The Carlyle GroupChina
Abcam (exited)
Active
EMV CapitalUK
Data refreshed weekly · Sourced from public filings